Previous Close | 0.9160 |
Open | 0.9406 |
Bid | 0.0000 x 1000 |
Ask | 0.0000 x 1300 |
Day's Range | 0.8721 - 0.9499 |
52 Week Range | 0.8050 - 4.3400 |
Volume | |
Avg. Volume | 467,658 |
Market Cap | 103.676M |
Beta (5Y Monthly) | 1.76 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7710 |
Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.36 |
Subscribe to Yahoo Finance Plus to view Fair Value for OCX
IRVINE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today reports financial results for the second quarter 2022, ended June 30, 2022. Second Quarter and Recent Highlights: Recent rightsizing of organization to match new program priorities is expected to reduce headcount carrying costs
IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that its management team will participate at the following conferences: UBS Genomics 2.0 and MedTech Innovations SummitPresenting on Thursday, August 11, 2022 at 5:00 p.m. Eastern Time in Dana Point, California. The li
Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...